<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02053896</url>
  </required_header>
  <id_info>
    <org_study_id>ISU302-003</org_study_id>
    <nct_id>NCT02053896</nct_id>
  </id_info>
  <brief_title>A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease</brief_title>
  <official_title>A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISU Abxis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISU Abxis Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with
      Type 1 Gaucher disease previously treated with Imiglucerase.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>From Screening to Week 24</time_frame>
    <description>To evaluate the safety of ISU302 in patients with Type 1 Gaucher disease previously treated with Cerezyme® after administering ISU302 alternative to Cerezyme®</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>From Screening to Week 24</time_frame>
    <description>Measurement of blood glucocerebrosidase activity for pharmacokinetic assessment after initial study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin concentration</measure>
    <time_frame>From Screening to Week 24</time_frame>
    <description>Change in hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet count</measure>
    <time_frame>From Screening to Week 24</time_frame>
    <description>Change in platelet count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver and spleen volumes and liver function</measure>
    <time_frame>From Screening to Week 24</time_frame>
    <description>Changes in liver and spleen volumes and liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>biomarker levels</measure>
    <time_frame>From Screening to Week 24</time_frame>
    <description>Changes in biomarker levels (Acid Phosphatase, Angiotensin Converting Enzyme, and Chitotriosidase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skeletal status and bone mineral density</measure>
    <time_frame>From Screening to Week 24</time_frame>
    <description>Changes in skeletal status and bone mineral density</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>ISU302</arm_group_label>
    <description>15~60U/kg (once every 2 weeks for 6 months)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient diagnosed with type-1 Gaucher disease
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with type-1 Gaucher disease

          -  Patient who was stably treating Gaucher disease with Cerezyme® and who was maintaining
             the usage and dosage of Cerezyme® for at least 6 months prior to study drug
             administration

          -  Patient aged 2 years or higher

          -  Female patient with contraception during the study period (oral or injectable
             contraceptive hormones, intrauterine device, physical devices using condom, sponge
             form, jelly, and femidom, and abstinence)

          -  Patient who signed the informed consent form after hearing the detailed explanation
             about this study

               -  Definition of the stable treatment of type-1 Gaucher disease:

          -  No neurologic deficit

          -  Normal hemoglobin concentration, and platelet count that has increased to ≥100,000/㎣,
             or maintained to 100,000/㎣

          -  Normal or no deteriorated bone mineral density

          -  Normal or no deteriorated splenomegaly or hepatomegaly

        Exclusion Criteria:

          -  Patient who participated in other clinical studies within 90 days before study drug
             administration

          -  Patient with unstable hemoglobin and platelet counts for at least 6 months before
             study drug administration

          -  Patient with hypersensitivity to Cerezyme®

          -  Patient positive to HIV antibody, hepatitis B antigen, and hepatitis C antibody

          -  Patient with Fe, folic acid, or vitamin B12-deficcient anemia

          -  Patient who received miglustat within 6 months before study drug administration

          -  Patient who received erythrocyte growth factor or chronic systemic corticosteroids
             within 6 months before study drug administration

          -  Patient who had clinically significant splenic obstruction within 12 months before
             study drug administration

          -  Pregnant or lactating patient

          -  Patient who had serious concurrent diseases such as infectious diseases or
             drug-addicted patient

          -  Patient who was considered inappropriate for this study by the investigators or
             sub-investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2014</study_first_posted>
  <last_update_submitted>February 3, 2014</last_update_submitted>
  <last_update_submitted_qc>February 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type I Gaucher</keyword>
  <keyword>ISU302</keyword>
  <keyword>Imiglucerase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

